Werewolf Therapeutics, Inc. (HOWL)
0.9744
-0.01
(-1.43%)
USD |
NASDAQ |
Sep 11, 11:36
Werewolf Therapeutics Profit Margin (Quarterly) : 17.48% for June 30, 2026
Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 17.48% |
| March 31, 2026 | |
| December 31, 2025 | |
| September 30, 2025 | |
| June 30, 2025 | |
| March 31, 2025 | |
| December 31, 2024 | |
| September 30, 2024 | |
| June 30, 2024 | -1.51K% |
| Date | Value |
|---|---|
| March 31, 2024 | -2.18K% |
| December 31, 2023 | -799.7% |
| September 30, 2023 | -140.5% |
| June 30, 2023 | -63.09% |
| March 31, 2023 | -268.4% |
| December 31, 2022 | -163.8% |
| September 30, 2022 | -240.3% |
| June 30, 2022 | -351.8% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Profit Margin (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | -237.8% |
| Oncolytics Biotech, Inc. | -- |
| Sangamo Therapeutics, Inc. | -2.15K% |
| Sarepta Therapeutics, Inc. | -1.22% |
| Anixa Biosciences, Inc. | -- |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | -139.1% |
| Return on Assets | -53.45% |
| Return on Invested Capital | -63.13% |
| Gross Profit Margin (Quarterly) | 88.32% |
| Operating Margin (Quarterly) | 40.65% |
| Return on Net Operating Assets | -411.3% |